Chemotherapy dose density in early-stage breast cancer and non-Hodgkin's lymphoma

Pharmacotherapy

Volumn 24, Issue 10 II, 2004, Pages 1347-1357

  Goldspiel, Barry R ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Colony stimulating factor; Dose dense chemotherapy; Early stage breast cancer; Hematologic toxicity; Neutropenia; Non Hodgkin's lymphoma; Standard dose chemotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; COLONY STIMULATING FACTOR; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 11; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ANEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; DISEASE SEVERITY; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; EARLY CANCER; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; HUMAN; MUCOSA INFLAMMATION; NEUROTOXICITY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PREVALENCE; QUALITY OF LIFE; REVIEW; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; HUMANS; LYMPHOMA, NON-HODGKIN;

EID: 4644289906     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.14.1347.43154     Document Type: Review

References (75)

1. Epelbaum R, Faraggi D, Ben-Arie Y, et al. Survival of diffuse large cell lymphoma. A multivarlate analysis including dose intensity variables. Cancer 1990;66:1124-9.
2. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-77.
3. Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkins lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'etude des lymphomes de l'adulte). Ann Oncol 1993;4:651-6.
4. Bonadonna G, Zambetti M, Valagussa P. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 1995;273:542-7.
5. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The cancer and leukemia group B. J Natl Cancer Inst 1998;90:1205-11.
6. Norton L. Evolving concepts in the systemic drug therapy of breast cancer. Semin Oncol 1997;24(4 suppl 10):S10-13.
7. Piccart MJ, Biganzoli L, Di Leo A. The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur J Cancer 2000;36(suppl 1):S4-10.
8. Hudis C. New approaches to adjuvant chemotherapy for breast cancer. Pharmacotherapy 1996;16(3 pt2):88S-93.
9. Fisher B, Anderson S, DeCillis A, et al. Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from national surgical adjuvant breast and bowel project B-25. J Clin Oncol 1999;17:3374-88.
10. Fisher B, Anderson S, Wickerham DL, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from national surgical adjuvant breast and bowel project B-22. J Clin Oncol 1997;15:1858-69.
11. Henderson IC, Berry DA, Demetri GD, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976-83.
12. Bartlett NL, Petroni GR, Parker BA, et al. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: cancer and leukemia group B studies 8852 and 8854. Cancer 2001;92:207-17.
13. Fisher RI. Diffuse large-cell lymphoma. Ann Oncol 2000;11(suppl 1):29-33.
14. Savarese DM, Hsieh C, Stewart FM. Clinical impact of chemotherapy dose escalation in patients with hematologic malignancies and solid tumors. J Clin Oncol 1997;15:2981-95.
15. Siu LL, Tannock IF. Chemotherapy dose escalation: case unproven. J Clin Oncol 1997;15:2765-8.
16. Frei E III, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980;69:585-94.
17. Hudis C. Dose-dense chemotherapy for breast cancer: the story so far. Br J Cancer 2000;82:1897-9.
18. Coldman AJ, Goldie JH. Impact of dose-intense chemotherapy on the development of permanent drug resistance. Semin Oncol 1987;14(4 suppl 4):29-33.
19. Johnston EM, Crawford J. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Semin Oncol 1998;25:552-61.
20. Itoh K, Ohtsu T, Wakita H, et al. Dose-escalation study of CHOP with or without prophylactic G-CSF in aggressive non-Hodgkin's lymphoma. Ann Oncol 2000;11:1241-7.
21. Santoro A, Balzarotti M, Tondini C, et al. Dose-escalation of CHOP in non-Hodgkin's lymphoma. Ann Oncol 1999;10:519-25.
22. Talbot SM, Westerman DA, Grigg AP, et al. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors. Ann Oncol 1999;10:907-14.
23. Gordon LI, Young M, Weller E, et al. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: analysis of response, toxicity, and dose intensity. Blood 1999;94:3307-14.
24. Ellis GK, Livingston RB, Gralow JR, Green SJ, Thompson T. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer. J Clin Oncol 2002;20:3637-43.
25. Vose JM, Crump M, Lazarus H, et al. Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. J Clin Oncol 2003;21:514-19.
26. Holmes FA, Jones SE, O'Shaughnessy J, et al. Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in woman with breast cancer. Ann Oncol 2002;13:903-9.
27. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003;14:29-35.
28. Moore TD, Patel T, Segal, ML, et al. A single pegfilgrastim dose per cycle supports dose-dense (q14d) CHOP-R in patients with non-Hodgkin's lymphoma [abstr]. Blood 2003;102:641a.
29. Younes A, Fayad L, Pro B, Romaguera J, Ha CS, Wilder R. Safety and efficacy of prophylactic pegfilgrastim in patients with Hodgkin's disease receiving ABVD chemotherapy [abstr]. Blood 2002;100:171b.
30. Riedel R, Garst J, Dunphy F, et al. Dose-dense carboplatin/vinorelbine with pegfilgrastim support for the treatment of thoracic malignancies [abstr]. Proc Am Soc Clin Oncol 2003;22:703.
31. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-9.
32. Mayers C, Panzarella T, Tannock IF. Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91:2246-57.
33. Bonneterre J, Roché H, Bremond A, et al. Results of a randomized trial of adjuvant chemotherapy with FEC 50 vs FEC 100 in high risk node-positive breast cancer patients [abstr]. Proc Am Soc Clin Oncol 1998;17:124a.
34. Hudis C, Seidman A, Baselga J, et al. Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy. J Clin Oncol 1999;17:93-100.
35. Fornier MN, Seidman AD, Theodoulou M, et al. Doxorubicin followed by sequential paclitaxel and cyclophosphamide versus concurrent paclitaxel and cyclophosphamide: 5-year results of a phase II randomized trial of adjuvant dose-dense chemotherapy for women with node-positive breast carcinoma. Clin Cancer Res 2001;7:3934-41.
36. Citron ML, Berry DA, Cirrincione C, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of intergroup trial C9741/cancer and leukemia group B trial 9741. J Clin Oncol 2003;21:1431-9. (Erratum in J Clin Oncol 2003;21:2226.)
37. Lee KW, Kim DY, Yun T, et al. Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 2003;98:2651-6.
38. Wolf M, Matthews J, Stone J, et al. Dose-intensification does not improve outcome in aggressive non-Hodgkin's lymphoma (NHL). Report of a randomized trial by the Australasian leukemia and lymphoma group (ALLG) [abstr]. Blood 2000;96:832a.
39. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 1995;13:2916-23.
40. Bosly A, Sonet A, Salles G, et al. Superiority of late over early intensification in relapsing/refractory aggressive non-Hodgkin's lymphoma: a randomized study from the GELA: LNH PR 98 [abstr]. Blood 1997;90:594a.
41. Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
42. Fisher RI. Autologous stem-cell transplantation as a component of initial treatment for poor-risk patients with aggressive non-Hodgkin's lymphoma: resolved issues versus remaining opportunity. J Clin Oncol 2002;20:4411-12.
43. Hahn T, Wolff SN, Czuczman M, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2003;7:308-31.
44. Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. J Clin Oncol 1997;15:1131-7.
45. Gregory SA, Case DC, Bosserman L, et al. Fourteen-day CHOP supported with granulocyte colony-stimulating factor in patients with aggressive non-Hodgkin's lymphoma: results of a phase II study. Clin Lymphoma 2003;4:93-8.
46. Blayney DW, LeBlanc ML, Grogan T, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase 11 study of the southwest oncology group (SWOG 9349). J Clin Oncol 2003;21:2466-73.
47. Wunderlich A, Kloess M, Reiser M, et al. Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German high-grade non-Hodgkin's lymphoma study group (DSHNHL). Ann Oncol 2003;14:881-93.
48. Pfreundschuh M, Trümper L, Kloess M, et al. 2-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004;104:634-41.
49. Pfreundschuh M, Trûmper L, Kloess M, et al. 2-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004;104:626-33.
50. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
51. Link BK, Budd GT, Scott S, et al. Delivering adjuvant chemotherapy to women with early-stage breast carcinoma: current patterns of care. Cancer 2001;92:1354-67.
52. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-31.
53. Dale DC, Crawford J, Agboola O, Lyman GH. Febrile neutropenia and reduced dose intensity in patients with aggressive non-Hodgkin's lymphoma (NHL) treated with CHOP and CNOP. Presented at the 40th annual meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8 2004.
54. de Graaf H, Willemse PH, Bong SB, et al. Dose intensity of standard adjuvant CMF with granulocyte colony-stimulating factor for premenopausal patients with node-positive breast cancer. Oncology 1996;53:289-94.
55. Rivera E, Erder MH, Moore TD, et al. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model. Cancer 2003;98:222-8.
56. Lyman GH, Kuderer NM, Djulbegovic B. Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 2002;112:406-11.
57. Siena S, Piccart MJ, Holmes FA, et al. A single dose of pegfilgrastim per chemotherapy cycle allows most patients to receive an average dose intensity (ARDI) ≥ 85%. Presented at the 25th annual San Antonio breast cancer symposium, San Antonio, TX, December 11-14, 2002.
58. Morrison VA, Picozzi V, Scott S, et al. The impact of age on delivered dose intensity and hospitalizations for febrile neutropenia in patients with intermediate-grade non-Hodgkin's lymphoma receiving initial CHOP chemotherapy: a risk factor analysis. Clin Lymphoma 2001;2:47-56.
59. Balducci L, Corcoran MB. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 2000;14:193-212.
60. Dale D, Zelenetz AD, Crawford J, Lyman GH. Undertreatment as a cause of poor outcomes in elderly patients: evidence from surveys of practice patterns in early-stage breast cancer and non-Hodgkin's lymphoma. Presented at the 7th international conference on geriatric oncology: cancer in the elderly, Boston, MA, September 27-28, 2002.
61. Christman K, Muss HB, Case LD, Stanley V. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont oncology association experience. JAMA 1992;268:57-62.
62. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the international breast cancer study group trial VII. J Clin Oncol 2000;18:1412-22.
63. Lyman GH, Crawford J, Dale D, Chen H, Agboola Y, Lininger L. Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy [abstr]. Proc Am Soc Clin Oncol 2001;20:394a.
64. Balducci L. The geriatric cancer patient: equal benefit from equal treatment. Cancer Control 2001;8(2 suppl):1-25, 27-8.
65. Jacobson JO, Grossbard M, Shulman LN, Neuberg D. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis. Clin Lymphoma 2000;1:211-18.
66. Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 1992;80:1430-6.
67. Zagonel V, Babare R, Merola MC, et al. Cost-benefit of granulocyte colony-stimulating factor administration in older patients with non-Hodgkin's lymphoma treated with combination chemotherapy. Ann Oncol 1994;5(suppl 2):127-32.
68. Bertini M, Freilone R, Vitolo U, et al. P-VEBEC: a new 8-weekly schedule with or without rG-CSF for elderly patients with aggressive non-Hodgkin's lymphoma (NHL). Ann Oncol 1994;5:895-900.
69. Zinzani PL, Pavone E, Storti S, et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997;89:3974-9.
70. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic lymphoma group randomized trial. Blood 2003;101:3840-8.
71. Doorduijn JK, van der Holt B, van Imhoff GW, et al. CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3041-50.
72. Fortner BV, Stolshek B, Schwartzberg LS, et al. Decline in absolute neutrophil count (ANC) is associated with lower quality of life (QOL) in cancer patients receiving docetaxel [abstr]. Proc Am Soc Clin Oncol 2002;21:247b.
73. Okon TA, Fortner BV, Schwartzberg L, et al. Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN) [abstr]. Proc Am Soc Clin Oncol 2002;21:275b.
74. McGuire WP III. High-dose chemotherapeutic approaches to ovarian cancer management. Semin Oncol 2000;27(3 suppl 7):41-6.
75. Booton R, Thatcher N. Chemotherapy in advanced nonsmall cell lung cancer: indication, intensity, and duration. Curr Opin Oncol 2002;14:191-8.